AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00093379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
Study NCT00093379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 50 mg/m\^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
Study NCT00093379 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (XRT)
Description: Undergo radiotherapy\* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. \*Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
Study NCT03897517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Botanical Blend
Description: Oral administration of capsules containing proprietary botanical blend 30 minutes prior to carbohydrate ingestion.
Study NCT03897517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of capsules containing rice flour (placebo) 30 minutes prior to carbohydrate ingestion.
Study NCT00888186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: intestinal gel, for continuous daytime infusion
Study NCT00888186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: intestinal gel, for continuous daytime infusion
Study NCT03835832 — intervention group
Intervention type: OTHER
Intervention: The participants do not receive any intervention for this study
Description: The participants do not receive any intervention for this study
Study NCT04156633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: conventional identification method: biochemical profiling or MALDI-TOF MS
Description: Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
Study NCT04156633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: new identification method: Biofire FilmArray© BCID panel
Description: The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
Study NCT04156633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: new identification method: metagenomic WGS
Description: shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)
Study NCT04466202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music with Structured Verbal Training
Description: Structured verbal training on prostate biopsy was given to the intervention group before the procedure, and then patients in this group listened to the music they preferred during the procedure with headphones.
Study NCT02155478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ISERT 250 (HOYA, Japan): a standard IOL
Study NCT02155478 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL
Study NCT01770132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasonography
Description: Undergo EUS-PDT
Study NCT01770132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo EUS-PDT
Study NCT01770132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT04434391 — intervention group
Intervention type: OTHER
Intervention: QF-PCR for GBS screening
Description: QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
Study NCT03828591 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intensive psychological support
Description: Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)
Study NCT03828591 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard psychological support
Description: Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
Study NCT04319107 — intervention group
Intervention type: OTHER
Intervention: ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.
Description: Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
Study NCT03377907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine in hematoma block
Description: ketamine used in local hematoma block only
Study NCT03377907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine in local intravenous anesthesia
Description: ketamine will be used with lidocaine in local intravenous anesthesia
Study NCT03377907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 2.5 mg/kg of lidocaine 2% in intravenous regional anesthesia
Study NCT00893321 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inferior Oblique Muscle Recession and Myectomy
Study NCT01689298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study NCT01689298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study NCT00782951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 28611
Description: single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
Study NCT00782951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulfate
Description: single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
Study NCT00782951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single IV dose of placebo after dental impaction surgery
Study NCT01292642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: individual CBT once weekly, 50 minutes, for 10 weeks
Study NCT01292642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: 1. 21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~2. 14 m g patch for 8 weeks, then 7 mg patch for 2 weeks
Study NCT03138538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: M8891
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Study NCT05054972 — intervention group
Intervention type: PROCEDURE
Intervention: Exclusion of the aortic aneurysm.
Description: Surgical procedure in which an aortic aneurysm is excluded.
Study NCT01860924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: vigorous intensity exercise
Study NCT01860924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: education
Study NCT01652885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 2%
Description: AN2728 Topical Ointment, 2%
Study NCT03189875 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: Participants will be followed as per local routine clinical practice
Study NCT01395394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
Study NCT01395394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Challenge
Description: At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
Study NCT00641251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intensive medical management
Description: IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
Study NCT00641251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RYGB & IMM
Description: Roux-en-Y gastric bypass Surgery combined with intensive medical management
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative education (standard of care)
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-operative education (standard of care)
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home health care visits (standard of care)
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home health care visits (standard of care)
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up post-operative visits
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up post-operative visits
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Data Collection Form
Description: -Form that contains date, area to record number of pouches, and if home health care visit took place.
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Data Collection Form
Description: -Form that contains date, area to record number of pouches, and if home health care visit took place.
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare Utilization Form
Description: * Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~* Form allows patient to record reason for visit and date of visit
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthcare Utilization Form
Description: * Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~* Form allows patient to record reason for visit and date of visit
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The City of Hope QOL Survey for Ostomy Patients
Description: * Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~* Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem.
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The City of Hope QOL Survey for Ostomy Patients
Description: * Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~* Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem.
Study NCT02658123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call with CWOCN or PA
Study NCT04106700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
Study NCT00586261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg daily for 6 months
Study NCT00586261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30 mg daily for 6 months
Study NCT00586261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: 0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
Study NCT00586261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: 0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
Study NCT04163809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Oculus Go headset
Description: The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
Study NCT03011346 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symetis ACURATE neo/TF transfemoral TAVI system
Description: Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
Study NCT03011346 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards Sapien 3 Transcatheter Heart Valve
Description: Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
Study NCT02229071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib(200mg)
Description: Donafenib 200mg,bid,po
Study NCT02229071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donafenib(300mg)
Description: Donafenib 300mg,bid,po
Study NCT01197326 — intervention group
Intervention type: DEVICE
Intervention: use of the MP5 EWS patient monitor
Description: All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
Study NCT04475055 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostisches Interview bei psychischen Störungen (DIPS)
Description: The DIPS is a structured interview which assesses the most frequent psychological disorders. It can be delivered by trained clinicians and takes between 50-120 minutes. Its acceptance with patients is very good.
Study NCT00666458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: tablet, per oral, once daily
Study NCT00666458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: capsule, per oral, once daily
Study NCT01465906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tulobuterol
Description: patch, 2mg, qN, 3 months
Study NCT01465906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: 18ug, inhale, qD, 3 months
Study NCT01465906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: 18ug, inhale, qD, 3 months
Study NCT00650910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
Study NCT00650910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.5mg on Days 1 and 9
Study NCT00891605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: 150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Study NCT00891605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.
Study NCT04320238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human interferon Alpha-1b
Description: recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
Study NCT04320238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymosin alpha 1
Description: thymosin alpha 1 subcutaneous injection 1 time per week.
Study NCT02700490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia.
Study NCT02700490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia.
Study NCT01372904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate
Description: 0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level.
Study NCT03637933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic tattooing
Description: The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
Study NCT03637933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic tattooing
Description: The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
Study NCT03378076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
Study NCT03378076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAcs 40 mg
Description: Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
Study NCT03718507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
Study NCT03718507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose 24% Oral Solution
Description: 0.5 ml given orally 2 minutes before LISA procedure
Study NCT00489567 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample collection
Study NCT04190225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital/social media intervention
Description: Participants will receive individual counseling, access to an individually tailored website, guided goal setting via texts, access to a study Instagram account, and a wearable tracker (Fitbit)
Study NCT03628014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inpatient-care program
Description: Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~* Daily orientation and visiting program~* Basic active movements~* Meal assistance~* Recreational activities
Study NCT01240161 — intervention group
Intervention type: DRUG
Intervention: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
Description: Each patient will have 0-3 or more FLT-PET brain scans.
Study NCT02242955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: 40 mg per day.
Study NCT02242955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: 40 mg per day.
Study NCT03986489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based dance/movement therapy (M-DMT)
Description: M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each online session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.
Study NCT03986489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic pain social support group
Description: The therapist will facilitate online open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change.~Each week, SSG participants will receive emails with brief information about the topic discussed during the group session.
Study NCT00084123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch Therapy
Study NCT00084123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy